Zions Bancorporation’s Nektar Therapeutics NKTR Stock Holding History

Zions Bancorporation’s Portfolio NKTR Stock Details NKTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-4	Closed	-$1K	–	988
2019 Q3	$1K	Hold	4	–	–	﹤0.01%	937
2019 Q2	$2K	Sell	4 -5	-56%	-$2.51K	﹤0.01%	817
2019 Q1	$4K	Buy	+9	New	+$5.33K	﹤0.01%	793

Other funds holding NKTR

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return

Zions Bancorporation's NKTR Position: Q4 2019 in Review

Zions Bancorporation sold out of Nektar Therapeutics (NKTR) in Q4 2019, closing a stake of 4 shares — an estimated $1K sold.

Zions Bancorporation first reported a position in NKTR in Q1 2019 and held it in 3 quarters. The position peaked at $4K in Q1 2019. 281 funds tracked by Wall St. Rank hold NKTR as of Q4 2019.

Zions Bancorporation reported no remaining Nektar Therapeutics position as of Q4 2019 after selling out during the quarter.
Zions Bancorporation sold 4 Nektar Therapeutics shares in Q4 2019, an estimated $1K.
Zions Bancorporation first reported a position in Nektar Therapeutics in Q1 2019 and held it in 3 quarters.
Zions Bancorporation's Nektar Therapeutics position peaked at $4K in Q1 2019.
281 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q4 2019.

Based on Zions Bancorporation's 13F filing for Q4 2019, filed 14 Feb 2020.